The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
暂无分享,去创建一个
[1] U. Tebbe,et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. , 1993, Journal of the American College of Cardiology.
[2] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.
[3] J. Hsia,et al. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators. , 1992, Journal of the American College of Cardiology.
[4] M. Pfisterer,et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. , 1992, British heart journal.
[5] J. Anderson,et al. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. , 1992, Journal of the American College of Cardiology.
[6] P. Armstrong,et al. Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. TPAT Study Group. , 1991, Journal of the American College of Cardiology.
[7] R. Califf,et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. , 1990, Circulation.
[8] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.. MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.
[9] U. Tebbe,et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.
[10] F. Werf. DISCREPANCIES BETWEEN THE EFFECTS OF CORONARY REPERFUSION ON SURVIVAL AND LEFT VENTRICULAR FUNCTION , 1989, The Lancet.
[11] I. Belenkie,et al. Importance of effective, early and sustained reperfusion during acute myocardial infarction. , 1989, The American journal of cardiology.
[12] R. Califf,et al. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality. , 1989, Journal of the American College of Cardiology.
[13] P W Serruys,et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. , 1988, Circulation.
[14] R Roberts,et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.
[15] F H Sheehan,et al. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. , 1987, Circulation.
[16] A. Ross,et al. The influence of residual coronary stenosis on size of infarction after reperfusion in a canine preparation. , 1986, Circulation.
[17] M. Gotsman,et al. Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. , 1985, The New England journal of medicine.
[18] F. Sheehan,et al. Time from onset of symptoms to thrombolytic therapy: a major determinant of myocardial salvage in patients with acute transmural infarction. , 1985, Journal of the American College of Cardiology.
[19] R. W. Brower,et al. RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.
[20] S. Chierchia,et al. Prevention of myocardial infarction by very early treatment with intracoronary streptokinase. Some clinical observations. , 1984, The New England journal of medicine.
[21] J. Greenfield,et al. Functional improvement of jeopardized myocardium following intracoronary streptokinase infusion in acute myocardial infarction. , 1983, The Journal of clinical investigation.
[22] E. Braunwald,et al. Time course of functional and biochemical recovery of myocardium salvaged by reperfusion. , 1983, Journal of the American College of Cardiology.
[23] R. A. Groeneveld,et al. Practical Nonparametric Statistics (2nd ed). , 1981 .
[24] H. Dodge,et al. The use of biplane angiocardigraphy for the measurement of left ventricular volume in man. , 1960, American heart journal.